Skip to main content
SpringerLink
Log in

The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases

  • Histamine and Kinins
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Platelet aggregation in response to 5-hydroxytryptamine was investigated in 40 normal subjects, in 45 patients with acute myocardial infarction, and in 65 patients with peripheral arterial obstructive disease. It was found that of the 110 patients with cardiovascular disease, 40% had a biphasic irreversible platelet aggregation, whereas this phenomenon occurred in only 7.5% of the normal population. A double-blind placebo-controlled study further showed that a subacute treatment with ketanserin, a selective 5-HT2-receptor antagonist both on platelets and on vascular tissue, efficiently abolished the irreversible platelet aggregation in patients hyperreactive to 5-hydroxytryptamine. In an additional open study, including 10 patients with peripheral arterial obstructive disease, a chronic treatment with ketanserin 40 mg t.i.d. for a period of 3 months significantly suppressed the primary platelet aggregation to 5-HT at 2×10−5 M and at 2×10−6 M and significantly lowered the plasma betathromboglobulin levels. Since 5-HT is a potent mediator of vasospam, treatment with ketanserin might be of therapeutic value in atherosclerotic diseases, where platelet activation is thought to be involved.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. E.M.M. Besterman andM.P.T. Gillet,Influence of lysolecithin on platelet aggregation initiated by 5-hydroxytryptamine, Nature, Lond.241, 223–224 (1973).

    Google Scholar 

  2. J.G. White,A biphasic response of platelets to serotonin, Scand. J. Haematol.7, 145–151 (1970).

    PubMed  Google Scholar 

  3. R.I. Handin, M. McDonough andM. Lesch,Elevation of platelet factor four in acute myocardial infarction: measurement by radioimmunoassay, J. Lab. clin. Med.91, 340–349 (1978).

    PubMed  Google Scholar 

  4. L.H. Green, E. Scroppian andR.I. Handin,Platelet activation during exercise-induced myocardial ischemia, New Engl. J. Med.302, 193–197 (1980).

    PubMed  Google Scholar 

  5. M.B. Schwartz, J. Haniger, S. Timmons andG.C. Friesinger,Platelet aggregates in ischemic heart disease, Thromb. Haemostatis434, 185–188 (1980).

    Google Scholar 

  6. G. Baele, H. Bogaerts, D.L. Clement, R. Pannier andF. Barbier,Platelet activation during treadmill exercise in patients with chronic peripheral arterial disease, Thromb. Res.23, 215–223 (1981).

    Article  PubMed  Google Scholar 

  7. H.H. Rotmensch, P.H. Vlasses, K.L. Carpentier, L.F. D'Amelio, B.N. Swanson andR.K. Ferguson,Plasma platelet products and exercise-induced myocardial ischemia, J. Lab. clin. Med.102, 63–69 (1983).

    PubMed  Google Scholar 

  8. P.P. Steele, H.S. Welly, H. Davies andE. Genton,Platelet function studies in coronary artery disease, Circulation48, 1194–1200 (1973).

    PubMed  Google Scholar 

  9. F. Dreyfuss andJ. Zahavi,Adenosine diphosphateinduced platelet aggregation in myocardial infarction and ischemic heart disease, Atherosclerosis17, 107–120 (1973).

    Article  PubMed  Google Scholar 

  10. M. Salky andM. Dugdale,Platelet abnormalities in ischemic heart disease, Am. J. Cardiol.32, 612–617 (1973).

    PubMed  Google Scholar 

  11. J.E. Leysen, F. Awouters, L. Kennis, P.M. Laduron, J. Vanderberk andP.A.J. Janssen,Receptor binding profile of R 41 468, a novel antagonist at 5-HT 2-receptors, Life Sci.28, 1015–1022 (1981).

    Article  PubMed  Google Scholar 

  12. F. De Clerck, J.L. David andP.A.J. Janssen, Serotonergic amplification mechanisms in blood platelets. In5-Hydroxytryptamine in Peripheral Reactions, pp. 83–94 (Eds.F. De Clerck andP. Vanhoutte). Raven Press, New York, 1982.

    Google Scholar 

  13. J.M. Van Nueten, J. Vanberk, R. Xhonneux, T. Verbeuren andP.M. Vanhoutte,Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT 2-serotonergic receptors, J. Pharmac. exp. Ther.218, 217–230 (1981).

    Google Scholar 

  14. F. De Clerck, J.L. David andP.A.J. Janssen,Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT 2-receptor antagonist, Agents and Actions12, 388–397 (1982).

    PubMed  Google Scholar 

  15. P.M. Vanhoutte, Heterogenicity in vascular smooth muscle. InMicrocirculation, Vol. 2, pp. 181–309 (Eds.G. Kaley andB.M. Altura). University Pail Press, 1978.

  16. C.W. Pumphrey andJ. Dawes,Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction, Am. J. Cardiol.50, 1258–1261 (1982).

    Article  PubMed  Google Scholar 

  17. M.E. Stewart, J.T. Douglas, G.D.O. Lowe, C.R.M. Prentice andC.D. Forbes,Prognostic value of betathromboglobulin in patients with transient cerebral ischaemia, Lancetii, 479–482 (1983).

    Article  Google Scholar 

  18. F.E. Preston, J.D. Ward, B.H. Marcola, N.R. Porter andW.R. Timberley,Elevated betathromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy, Lanceti, 238–240 (1978).

    Article  Google Scholar 

  19. J. Zahavi andV.V. Kakkar,Beta-thromboglobulin — a specific marker of in vivo platelet release reaction, Thromb. Haemostasis44, 23–29 (1980).

    Google Scholar 

  20. F. De Clerck, B. Xhonneux, J. Leysen andP.A.J. Janssen,The involvement of 5HT 2-receptor sites in the activation of cat platelets, Thromb. Res.33, 305–321 (1984).

    Article  PubMed  Google Scholar 

  21. J. Bevan andS. Heptinstall,Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets, Thromb. Res.30, 415–423 (1983).

    Article  PubMed  Google Scholar 

  22. R.P. Sorkin, J.M. Tokarsky, M.J. Huber-Smith, J.F. Steiger andD.S. McCann,In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction, Am. Heart J.104, 1255–1261 (1982).

    Article  PubMed  Google Scholar 

  23. F. De Clerck andJ.M. Van Nueten,Plateletmediated vascular contractions: Inhibition of the serotonergic component by ketanserin, Thromb. Res.27, 713–723 (1982).

    Article  PubMed  Google Scholar 

  24. A. Nevelsteen, W. Loots, F. De Clerck andA. De Gryse,Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT 2 receptor antagonist, Archs. int. Pharmacodyn. Thér.270, 268–279 (1984).

    Google Scholar 

  25. V. Verheyen, E. Vlaminckx, F. Lauwers, C. Van Den Broeck andL. Wouters,Serotonin-induced blood flow changes in the rat hind legs after unilateral ligation of the femoral artery. Inhibition by the S 2-receptor antagonist ketanserin, Archs int. Pharmacodyn. Thér.270, 280–298 (1984).

    Google Scholar 

  26. J.L. Blackshear, S. Orlandi, J.D. Garnic andN.K. Hollenberg,Serotonin induces large artery spasm in vivo via 5-HT 2 receptors, Circulation68, 197 (1983).

    Google Scholar 

  27. J. De Cree, J. Leempoels, W. De Cock, H. Geukens andH. Verhaegen,the antihypertensive effects of a pure and selective serotinin-receptor blocking agents (R 41 468) in elderly patients, Angiology32, 137–144 (1981).

    PubMed  Google Scholar 

  28. J. De Cree, J. Leempoels, H. Geukens, W. De Cock andH. Verhaegen, Are serotonergic mechanisms involved in high blood pressure? In5-hydroxytryptamine in peripheral reactions, pp. 183–192 (EdsF. De Clerck andP. Vanhoutte). Raven Press, New York, 1982.

    Google Scholar 

  29. G.J. Wenting, A.J. Man in 't Veld, A.J. Wottiez, F. Boomsma andM.A.D.H. Schalekamp,Treatment of hypertension with ketanserin, a new selective 5-HT 2-receptor antagonist, Brit. med. J.284, 537–539 (1982).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research Unit, St Bartholomeus, Jan Palfijn Hospital, B-2060, Merksem, (Belgium)

    J. De Cree, J. Leempoels, B. Demoen, V. Roels & H. Verhaegen

Authors
  1. J. De Cree
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Leempoels
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Demoen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Roels
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Verhaegen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Cree, J., Leempoels, J., Demoen, B. et al. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases. Agents and Actions 16, 313–317 (1985). https://doi.org/10.1007/BF01982865

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01982865

Keywords

Search

Navigation